



Practitioner's Docket No. MPI98-089CP2M

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Glucksmann, Maria A., et al.		
Application No.:	09/964,008	Group No.:	1646
Filed:	September 26, 2001	Examiner:	O'HARA, EILEEN B.
For:	15625 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR		

**Commissioner for Patents**  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY**

Dear Sir:

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier  
Limited Recognition Under 37 CFR §11.9(b)  
Customer Number 30405 or  
Millennium Pharmaceuticals, Inc.  
40 Landsdowne Street  
Cambridge, MA 02139

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. EV528716871US

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

Signature

**Sean Hunziker**

(type or print name of person certifying)

Date: June 13, 2005

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI98-089CP2M**

**This is not a Power of Attorney to the above-named practitioner.**

Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.

Please continue to forward all written and telephonic communications to Tracy M. Sioussat at the address and telephone number listed below.

**SIGNATURE of Practitioner of Record**

Respectfully submitted,

June 13, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat  
Tracy M. Sioussat  
Attorney/Agent for Applicant  
Reg. No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone: (617) 374-7679  
Facsimile - (617) 551-8820

**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATE PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)**

Mario Cloutier is hereby given limited recognition under 37 CFR 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

**Expires: December 29, 2006**

Harry I. Moatz

## **Director of Enrollment and Discipline**



Practitioner's Docket No. 5800-13B (35800/238853) (MPI98-089CP2M) **PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Glucksmann, Maria A., et al  
Application No.: 09/964,008 Group No.: 1646  
Filed: September 26, 2001 Examiner: O'HARA, EILEEN B.  
For: 15625 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR

**Commissioner for Patents**  
**Washington, D.C. 20231**

**REVOCATION OF PRIOR POWERS OF ATTORNEY**  
**AND APPOINTMENT OF NEW POWER OF ATTORNEY**

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on March 11, 2002, at Reel 012704, Frame 0342 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"  
Mailing Label No. EV292721934US

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker/Carolyn Willey  
(type or print name of person certifying)

Date: April 3, 2003

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted in competition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**COPY**

**Practitioner's Docket No. 5800-13B (35800/238853) (MPI98-089CP2M)**

Scott A. Brown, Reg. No. 32,724; Ian R. Silverman, Reg. No. 37,443; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenco, Reg. No. 38,945, Janice M. Klunder, Reg. No. 41,121; Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 50,609; and Paul J. Paglierani, Reg. No. 52,498

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group  
MILLENNIUM PHARMACEUTICALS, INC.  
75 Sidney Street  
Cambridge, MA 02139

and direct all telephone calls to Jean M. Silveri at 617-679-7336

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Typed Name: Jean M. Silveri

Title: Associate General Counsel

Dated: April 3, 2003